Higher cost of implementing Xpert® MTB/RIF in Ugandan peripheral settings: Implications for cost-effectiveness

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 9, 2016, Pages

  Hsiang, E ^a   Little, K M ^b   Haguma, P ^c   Hanrahan, C F ^d   Katamba, A ^c   Cattamanchi, A ^e   Davis, J L ^f,g   Vassall, A ^h   Dowdy, D ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b POPULATION SERVICES INTERNATIONAL   (United States)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f YALE UNIVERSITY   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cost benefit analysis; Diagnostic tests; Molecular diagnostic techniques; Routine; Tuberculosis

Indexed keywords

ARTICLE; BUDGET; CLINICAL EVALUATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPUTUM ANALYSIS; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; UGANDA; UGANDAN; CLINICAL TRIAL; DIAGNOSTIC TEST; ECONOMICS; EMPIRICAL RESEARCH; MICROBIOLOGY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; SPUTUM; UNCERTAINTY;

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EMPIRICAL RESEARCH; HUMANS; RIFAMPIN; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; UGANDA; UNCERTAINTY;

EID: 84982082401     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0200     Document Type: Article

References (32)

1. World Health Organization. Global tuberculosis report, 2015. WHO/HTM/TB/2015.22. Geneva, Switzerland: WHO, 2015.
2. World Health Organization. Policy statement: automated realtime nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF. WHO/HTM/TB/2011.4. Geneva, Switzerland: WHO, 2011.
3. Steingart K R, Schiller I, Horne D J, Pai M, Boehme C C, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane database Syst Rev. 2014; 1(1): CD009593.
4. World Health Organization. TB diagnostics and laboratory strengthening. Geneva, Switzerland: WHO, 2015.
5. World Health Organization. WHO monitoring of Xpert MTB/ RIF roll-out: procurements of GeneXperts and Xpert MTB/RIF cartridges. http://apps.who.int/tb/laboratory/xpertmap/. Geneva, Switzerland: WHO, 2014.
6. Whitelaw A, Peter J, Sohn H, et al. Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients. Eur Respir J 2011; 38: 1393-1397.
7. Abimbola T O, Marston B J, Date A A, Blandford J M, Sangrujee N, Wiktor S Z. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 60: e1-e7.
8. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLOS ONE 2012; 7: e36966.
9. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 2012; 17: 1142-1151.
10. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J 2013; 42: 708-720.
11. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLOS Med 2011; 8: e1001120.
12. Andrews J R, Lawn S D, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012; 26: 987-995.
13. Menzies N A, Cohen T, Lin H H, Murray M, Salomon J A. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLOS Med 2012; 9: e1001347.
14. Cox H S, Mbhele S, Mohess N, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLOS Med 2014; 11: 1-12.
15. Sachdeva K S, Raizada N, Sreenivas A, et al. Use of Xpert MTB/ RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLOS ONE 2015; 10: 1-18.
16. Hanrahan C F, Clouse K, Bassett J, et al. The patient impact of point-of-care vs. laboratory placement of Xpert MTB/RIF. Int J Tuberc Lung Dis 2015; 19: 811-816.
17. Abdurrahman S T, Emenyonu N, Obasanya O J, et al. The hidden costs of installing Xpert machines in a tuberculosis high-burden country: experiences from Nigeria. Pan Afr Med J 2014; 18: 1-5.
18. Hanrahan C F, Selibas K, Deery C B, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLOS ONE 2013; 8: e65421.
19. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014; 383: 424-435.
20. Churchyard G J, Stevens W S, Mametja L D, et al. Xpert MTB/ RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015; 3: e450-457.
21. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
22. Hanrahan C F, Haguma P, Ochom E, et al. Implementation of Xpert MTB/RIF in Uganda: missed opportunities to improve diagnosis of tuberculosis. Open Forum Infect Dis 2016; 3: ofw068.
23. Radelet S, Sachs J D. Shipping costs, manufactured exports, and economic growth. Presented at the Annual Meeting of the American Economics Association, Chicago, 3-5 January 1998. New York, NY, USA: Columbia University Academic Commons, 1998.
24. Foundation for Innovative New Diagnostics. Negotiated prices for Xpert® MTB/RIF and FIND country list. Geneva, Switzerland: FIND, 2013. http://www.finddiagnostics.org/about/what-we-do/successes/find-negotiated-prices/xpert-mtb-rif-with-warranty.html. Accessed May 2016.
25. Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization, 2003. http://www.who.int/choice/publications/p-2003-generalised-cea.pdf. Accessed May 2016.
26. Chihota V N, Ginindza S, McCarthy K, Grant A D, Churchyard G, Fielding K. Missed opportunities for TB investigation in primary care clinics in South Africa: experience from the XTEND trial. PLOS ONE 2015; 10: e0138149.
27. Hermans S, Nasuuna E, van Leth F, et al. Implementation and effect of intensified case finding on diagnosis of tuberculosis in a large urban HIV clinic in Uganda: a retrospective cohort study. BMC Public Health 2012; 12: 674.
28. Sekandi J N, List J, Luzze H, et al. Yield of undetected tuberculosis and human immunodeficiency virus coinfection from active case finding in urban uganda. Int J Tuberc Lung Dis 2014; 18: 13-19.
29. Salje H, Andrews J R, Deo S, et al. The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. PLOS Med 2014; 11: e1001674.
30. Pho M T, Deo S, Palamountain K M, Joloba M L, Bajunirwe F, Katamba A. Optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of Uganda. PLOS ONE 2015; 10: 1-14.
31. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013.16. Geneva, Switzerland: WHO, 2013.
32. Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis 2015; 211 (SUPPL. 2): S21-S28.